Alitair to Attend 37th Annual J.P. Morgan Healthcare Conference

January 4, 2019

Alitair Pharmaceuticals will attend the 37th annual J.P. Morgan Healthcare Conference from January 7-10, 2019 in San Francisco, California. The J.P. Morgan Healthcare Conference is one of largest conferences in the life sciences industry

Key members of the Alitair Executive Team will be available to meet with potential funders, partners and stakeholders. We will be prepared to discuss our business model and the status of the pipeline. Business Development opportunities exist in both co-development and licensing programs. This includes opportunities to license products for Canada and select markets in Asia and South America.

If you plan to attend conference and would like to meet with Alitair to discuss the company’s latest developments, please contact Frank Koos (SVP, Corporate and Business Development) at fkoos@alitair.com.

Alitair Forward-Looking Statement

The information contained in this January 2019 Communication may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements may be identified through the use of words such as “may”, "expects/excepted", "will", "anticipates", “allows”, "estimates", "believes", “provides” or by statements indicating certain actions "may", "could", "should" or "might" occur. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The information contained in this January 2019 Communication was current as of the date prepared and we specifically disclaim any obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise. (Version: 01.02.2019)